The National Institutes of Health will redirect funds to the Department of Defense for biodefense research, drawing sharp criticism from lawmakers. Sen. Patty Murray argues the deal transfers money to the Pentagon without proper oversight.

Critics suggest this marks a long-term effort to move biosecurity research out of the NIH entirely. A key point of contention involves NIH money funding work that NIH leadership has explicitly rejected. In a commentary earlier this year, NIAID and NIH heads advocated dropping biodefense research to focus on current American health threats.

Yet the new agreement allocates funds to protect against future pandemic strains and CBRN threats. This creates a paradox where the agency pays the Pentagon to conduct research its own leadership opposes. The agreement remains remarkably vague, making consequences difficult to predict until spending data emerges.

Lawmakers worry future Congress may prohibit such transfers, though recent actions suggest willingness to intervene. The deal highlights a significant shift in federal biosecurity priorities.